Aaron Wealth Advisors LLC Raises Stock Holdings in Novartis AG (NYSE:NVS)

Aaron Wealth Advisors LLC boosted its holdings in Novartis AG (NYSE:NVS) by 7.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,117 shares of the company’s stock after purchasing an additional 986 shares during the period. Aaron Wealth Advisors LLC’s holdings in Novartis were worth $1,374,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Legacy Investment Solutions LLC purchased a new position in shares of Novartis in the 3rd quarter worth about $28,000. Fortitude Family Office LLC raised its position in Novartis by 503.8% in the third quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after acquiring an additional 267 shares during the period. Clean Yield Group purchased a new position in Novartis in the third quarter valued at about $43,000. Brooklyn Investment Group bought a new position in shares of Novartis during the 4th quarter valued at approximately $55,000. Finally, Versant Capital Management Inc increased its stake in shares of Novartis by 782.0% during the 4th quarter. Versant Capital Management Inc now owns 785 shares of the company’s stock worth $76,000 after purchasing an additional 696 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Analyst Ratings Changes

NVS has been the subject of a number of recent research reports. Erste Group Bank reissued a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Finally, BMO Capital Markets increased their target price on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Two investment analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company. According to MarketBeat.com, Novartis has a consensus rating of “Hold” and an average target price of $121.50.

Novartis Stock Down 0.4 %

Shares of NYSE NVS opened at $97.51 on Friday. The business has a 50-day simple moving average of $100.61 and a two-hundred day simple moving average of $108.99. Novartis AG has a 52 week low of $92.35 and a 52 week high of $120.92. The company has a market cap of $199.30 billion, a P/E ratio of 11.32, a P/E/G ratio of 1.36 and a beta of 0.57. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The company had revenue of $12.82 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter in the previous year, the company earned $1.74 earnings per share. Research analysts anticipate that Novartis AG will post 7.63 earnings per share for the current fiscal year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.